Evidence map›Paper›PMID 20382706›Full record

ArticleThe American journal of pathology2010

Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.

Gizi Wildbaum, Yaniv Zohar, Nathan Karin

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. CCR8Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gizi WildbaumDepartment of Immunology, Bruce Rappaport Faculty of Medicine, Haifa, Israel. nkarin@tx.technion.ac.il.
Yaniv Zohar
Nathan Karin
Rappaport Family Institute for Research in the Medical Sciences · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study identifies within the Th1 subtype two distinct CD4(+) populations: those capable of transferring inflammatory autoimmunity and others that regulate its development by suppressing Th17 in an interferon (IFN)-gamma-dependent manner. These CD4(+)IFN-gamma(high)IL-4(low)IL-10(low)TGF-beta(low)FOXp3(-) cells in fact function as antigen-specific regulatory cells that restrain the development of autoimmunity by increasing the threshold of Th17 activation. We show that development of autoimmune conditions within the central nervous system is dependent on the Fas ligand-mediated apoptosis of these regulatory cells at early stages of disease. We also show that not only is the function of these cells IFN-gamma dependent but also that stable over expression of IFN-gamma in encephalitogenic CD4(+) T cells redirects their biological function to become antigen-specific regulatory cells. This may also explain, in part, the pleiotropic role of IFN-gamma in the regulation of autoimmunity, as previously observed by others.

Indexed as

AnimalsApoptosisCD4-Positive T-LymphocytesCell SeparationEncephalomyelitis, Autoimmune, ExperimentalFas Ligand ProteinFemaleFlow CytometryForkhead Transcription FactorsHumansInterferon-gammaInterleukin-17Interleukin-2 Receptor alpha SubunitMiceMice, Inbred C57BLT-Lymphocytes, Helper-InducerFas Ligand ProteinForkhead Transcription FactorsFoxp3 protein, mouseInterferon-gammaInterleukin-17Interleukin-2 Receptor alpha Subunit

Identifiers

PMID20382706
PMCPMC2877838
OpenAlexW2163824412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.